SAN FRANCISCO, Aug. 25, 2016 /PRNewswire/ -- EpiBiome, a precision microbiome engineering company, has been selected to participate in the KC Animal Health Investment Forum. The company will present data on its efforts to develop FDA-approved, zero-withholding-time alternatives to small-molecule antibiotics.
EpiBiome has initiated groundbreaking work in reducing the use of shared-class antibiotics—those shared between humans and animals—in agriculture. Instead of antibiotics, the company deploys bacteriophages, which are bacteria-specific viruses that can kill problematic bacteria, such as E. coli and S. aureus. The company's first disease indication is bovine mastitis, an inflammation of the udder tissue in dairy cows, which inflicts more than $2 billion in annual losses to the U.S. dairy industry due to reduced milk production and milk quality.
"Mastitis is the number-one reason antibiotics are administered to dairy cows today," said Nick Conley, CEO and co-founder of EpiBiome. "With our revealing proof-of-concept results, we see that there is the potential for another, more viable way to tackle the problem – one that is beneficial for agricultural producers as well as society."
EpiBiome is one of just twelve companies selected to present at the exclusive event. EpiBiome's presentation—given by Conley—will begin at 11:45 a.m. on Tuesday, Aug. 30 and will be held in the Grand Ballroom of the Kansas City Convention Center. The event will be attended by representatives from veterinary pharma and other stakeholders in the animal health space.
EpiBiome is a venture-backed precision microbiome engineering company with the mission of developing effective and sustainable FDA-approved therapies to combat infectious disease in humans and in agriculture without the use of small-molecule antibiotics.
The company's management team consists of Nick Conley, PhD (Chief Executive Officer & Co-founder), Aeron Tynes Hammack, PhD (Chief Operating Officer & Co-founder), Christina Tsai, PhD (VP of Asian Business Development & Co-founder), Lucia Mokres, DVM (Chief Medical Officer), and Bruno Marchon, PhD (Chief Technical Officer). EpiBiome is located at 201 Gateway Blvd., South San Francisco. For more information, visit http://www.epibiome.com.